

Read this for safe and effective use of your medicine

PART III: PATIENT MEDICATION INFORMATION

A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada.

REPLAGAL is used to
- treat patients with a confirmed diagnosis of Fabry Disease.

It has been approved *with conditions*. This means it has passed Health Canada's review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional.

Health Canada only gives an NOC/c to a drug that treats, prevents, or helps identify a serious or life-threatening illness. The drug must show promising proof that it works well, is of high quality, and is reasonably safe. Also, the drug must either respond to a serious medical need in Canada, or be much safer than existing treatments.

Drug makers must agree in writing to clearly state on the label that the drug was given an NOC/c, to complete more testing to make sure the drug works the way it should, to actively monitor the drug's performance after it has been sold, and to report their findings to Health Canada.

Pr **REPLAGAL**^{®*} agalsidase alfa for injection

Read this carefully before you start taking **REPLAGAL** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **REPLAGAL**.

What is **REPLAGAL** used for?

- **REPLAGAL** is used to treat patients with a confirmed diagnosis of Fabry Disease.

How does **REPLAGAL** work?

REPLAGAL is a long-term enzyme replacement therapy when the level of enzyme in the body is absent or lower than normal as in Fabry Disease.

What are the ingredients in **REPLAGAL**?

Medicinal ingredients: agalsidase alfa
Non-medicinal ingredients: polysorbate 20, sodium chloride, sodium hydroxide, sodium phosphate monobasic monohydrate, and water for injection.

REPLAGAL comes in the following dosage forms:

1 mg/mL concentrate for solution for injection.

Do not use **REPLAGAL** if:

- you are allergic (hypersensitive) to agalsidase alfa, the medicinal ingredient, or to any of the other ingredients in **REPLAGAL** or its container

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take **REPLAGAL. Talk about any health conditions or problems you may have, including if:**

- you experience any of the following during infusion with **REPLAGAL**:
 - High fever, chills, sweating, fast heart rate
 - Nausea or are vomiting
 - Headaches, feel light-headedness or fatigue
 - Hives
 - Swelling in your hands, feet, ankles, face, lips, mouth or throat which may cause difficulty in swallowing or breathing

Your doctor/nurse may stop the infusion temporarily (5 – 10 minutes) until the symptoms go away and then begin the infusion again.

Your doctor may also treat the symptoms with other medicines (antihistamines or corticosteroids). Most of the time you can still be given **REPLAGAL** even if these symptoms occur.

- you experience a severe allergic (anaphylactic-type) reaction. The administration of **REPLAGAL** will be immediately discontinued and an

appropriate treatment will have to be initiated by your doctor.

- treatment with REPLAGAL makes your body produce antibodies.
- you have advanced renal disease.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with REPLAGAL:

- Chloroquine
- Amiodarone
- Benoquin
- Gentamicin

How to take REPLAGAL:

REPLAGAL treatment should be supervised by a physician experienced in the management of patients with Fabry Disease or other inherited metabolic disease. Infusion of REPLAGAL at home may be considered for patients who are tolerating their infusions well.

REPLAGAL has to be diluted in 9 mg/mL (0.9%) sodium chloride solution before use. After dilution, REPLAGAL is given in a vein. This will usually be in your arm. The infusion will be given every 2 weeks. Each time you are treated, it will take 40 minutes for REPLAGAL to be given to you in a vein. Do not use REPLAGAL if you notice that there is discoloration or other foreign particles present.

Usual dose:

Adults:

The dose is an intravenous infusion (in a vein) of 0.2 mg for every kg you weigh over 40 minutes. This would be about 14 mg or four 5 mL vials (glass bottles) of REPLAGAL for an average size (70 kg) individual. The intravenous infusion will be given every 2 weeks.

Children and adolescents:

For children and adolescents 7-18 years old, a dose of 0.2 mg/kg every 2 weeks may be used.

Overdose:

There is no experience of overdose with REPLAGAL.

If you think you have taken too much REPLAGAL, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

What are possible side effects from using REPLAGAL:

These are not all the possible side effects you may feel when taking REPLAGAL. If you experience any side effects not listed here, contact your healthcare professional.

The most common side effects with REPLAGAL include headache, flushing, nausea, chills, fever, pain and fatigue.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop running infusion and get immediate medical help
	Only if severe	In all cases	
Common			
Dyspnea: trouble breathing			√
Tachycardia: Abnormally fast heart rate		√	
Palpitations: pounding or irregular heartbeat			√
Chest or throat tightness			√
Uncommon			
Anaphylactic reaction: severe allergic reaction			√
Hypersensitivity		√	

If you have a troublesome symptom or side effect that

is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at [MedEffect \(http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php\)](http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 1908C
Ottawa, ON
K1A 0K9
Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect \(http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php\)](http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store REPLAGAL in a refrigerator at 2 to 8°C.

Keep out of reach and sight of children.

If you want more information about REPLAGAL:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website \(http://hc-sc.gc.ca/index-eng.php\)](http://hc-sc.gc.ca/index-eng.php) or by calling 1-888-867-7426.

This leaflet was prepared by Shire Human Genetic Therapies, Inc. (US)

Canadian importer / distributor: Paladin Labs Inc., Quebec, Canada

* REPLAGAL is a registered trade-mark of Shire Human Genetic Therapies, Inc.

Last Revised 10 February 2017